首页> 外文期刊>Case Reports in Critical Care >Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience
【24h】

Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience

机译:新型2019年SARS-COV-2和HCOV-NL63在幼苗患者中的临界护理管理:芝加哥经验

获取原文
       

摘要

Background. SARS-CoV-2 is a newly emerged virus that has spread rapidly, exhibiting tremendous morbidity and mortality. Some potential pharmaceutical targets have been identified but are still lacking proper validation. Case Presentation. We describe the case of a young, immunosuppressed and critically ill patient with previous Influenza B infection, requiring extracorporeal membrane oxygenation, which was then followed, in the succeeding months, by SARS-CoV-2 infection complicated by severe adult respiratory distress syndrome. Her clinical course exhibited complications, including pulmonary embolism, acute kidney injury, pneumothorax, pneumomediastinum, multiple cardiac arrests, and eventually death. Conclusion. Coinfection with other respiratory pathogens and opportunistic infections are possible.
机译:背景。 SARS-COV-2是一种新出现的病毒,它迅速传播,发病率发病率和死亡率。已经确定了一些潜在的药物目标,但仍缺乏正确的验证。案例演示。我们描述了具有先前流感B感染的年轻,免疫抑制和危重病患者的病例,需要体外膜氧合,然后在后续几个月中,通过严重的成年呼吸窘迫综合征复杂的SARS-COV-2感染。她的临床课程表现出并发症,包括肺栓塞,急性肾损伤,气胸,肺炎,多重心脏骤停,最终死亡。结论。与其他呼吸道病原体和机会感染的繁殖是可能的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号